An in vivo CRISPR screen identified BAP1 as a potent tumor suppressor in undifferentiated pleomorphic sarcomas (UPS). BAP1-deficient sarcomas exhibit a markedly immunosuppressive tumor microenvironment. Researchers found that PLK1 is required for the growth and survival of these sarcomas, with elevated expression in human UPS where BAP1 is reduced. Pharmacologic inhibition of PLK1 with volasertib significantly suppressed tumor growth in mouse models. Furthermore, combining PLK1 inhibition with anti-PD-1 therapy enhanced tumor control and improved survival.
This retrospective study investigated the impact of additional EWSR1 rearrangements on treatment outcomes in Ewing sarcoma. Analyzing a national cancer genomic database (C-CAT) of 90 cases, researchers found that the presence of coexisting EWSR1 rearrangements, beyond the primary EWSR1-ETS fusion, was associated with higher rates of disease progression on first-line chemotherapy. A representative case highlighted primary resistance to multiple lines of therapy in a patient with an additional ETS1-EWSR1 fusion, contrasting with a good response observed with an isolated EWSR1-FLI1 fusion. These findings suggest that these additional rearrangements may hold significant prognostic implications and warrant further investigation to optimize treatment strategies.